COVID vaccine: Three doses of the Cuban “Soberana” offer 92% effectiveness

Cuba’s anticovid vaccine has become one of the most promising to combat the pandemic. The island is one of the Latin American regions that has shown great leadership, since the prohibition of relations with the United States has prevented vaccines such as Pfizer, Moderna and Johnson & Johnson from immunizing their population. However, the effectiveness of “Sovereign 02”, according to the most recent clinical trials, grants up to 92.4% immunity against the SARS-CoV-2 virus.

“It was better, to protect our population, to be independent,” said Vicente Vérez Bencomo, general director of the Finlay Institute of Vaccines, in Havana, in a publication of “Nature.”

Medical experts were surprised, after an arduous stage of clinical phases, in which Soberana 02 and Abdala, another of the Cuban biologics, successfully passed the reliability protocols.

Soberana 02 also demonstrated in its most recent trials a 90% safety, when it is combined with a related vaccine, that is, designed with the same methodology (conjugate vaccines). This mixture is effective, according to its creators, against the “Delta” variant, one of the most worrying mutations.

In turn, Abdala, produced at the Center for Genetic Engineering and Biotechnology (CIGB), has registered more than 92% effectiveness -in the application of three doses-, after the evaluations corresponding to phase three, in which they participated more than 48 thousand volunteers.

Derived from its reliability, both drugs were approved by the Cuban regulatory agency (CECMED) for emergency use, in the last months of July and August, in the population over 18 years of age. Immunization of the children took place a couple of months later and, currently, 89% of the population has the complete vaccination schedule.

The efficacy of these anticovid treatments already has the approval of other regions around the world, such as Venezuela, Vietnam, Iran and Nicaragua, which will soon begin to administer it to their populations.

Three doses of Sovereign equals 92% efficacy

After the application of two doses of Soberana 02, the scientists were given the task of experimenting with the administration of a booster injection of Soberana Plus. This combination favored the immune response of the inoculated people.

One of the advantages of these types of vaccines, compared to innovative messenger RNA (mRNA) treatments such as those of Pfizer and Moderna, is that they do not need to be refrigerated, so their production can be increased and accelerated.

Promptness, in a context where an immediate response against the disease would prevent the emergence of new, more contagious and serious variants is key, said Craig Laferrière, head of vaccine development at Novateur Ventures in Toronto, Canada.

In addition, according to Laferrière, Soberana 02 and Abdala also produce fewer side effects than the biologics of AstraZeneca and Johnson & Johnson, both based on adenovirus.

However, there are other factors that are not so favorable around its manufacture, since many of the vaccines that take proteins from bacteria or viruses are produced in hamster ovary cells, which requires more time than other methods to manufacture this type of vaccine.



Read also

Leave a Reply

Your email address will not be published. Required fields are marked *